TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Bank of Montreal Can

Bank of Montreal Can grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 1.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,973 shares of the company’s stock after buying an additional 809 shares during the quarter. Bank of Montreal Can owned 0.21% of TransMedics Group worth $11,136,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMDX. Algert Global LLC grew its holdings in TransMedics Group by 119.1% during the 3rd quarter. Algert Global LLC now owns 39,048 shares of the company’s stock worth $6,131,000 after acquiring an additional 21,223 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after buying an additional 6,634 shares during the last quarter. Intech Investment Management LLC bought a new position in TransMedics Group during the 3rd quarter worth approximately $2,167,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after acquiring an additional 64,872 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $1,059,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.5 %

Shares of NASDAQ:TMDX opened at $86.71 on Monday. The company has a 50 day moving average of $111.69 and a 200-day moving average of $136.16. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.91 billion, a P/E ratio of 92.24 and a beta of 2.08. TransMedics Group, Inc. has a twelve month low of $68.84 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the company earned ($0.12) earnings per share. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, analysts anticipate that TransMedics Group, Inc. will post 1.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TMDX. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. TD Cowen reduced their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. JPMorgan Chase & Co. dropped their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Finally, Needham & Company LLC reissued a “hold” rating and set a $109.00 price target on shares of TransMedics Group in a report on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $131.80.

Insider Buying and Selling

In other news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,958 shares of company stock valued at $3,470,328 over the last three months. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.